These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 14511021)

  • 21. Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia.
    Ramar K; Potti A; Mehdi SA
    J Clin Oncol; 2003 Jan; 21(1):172-3. PubMed ID: 12506189
    [No Abstract]   [Full Text] [Related]  

  • 22. Hypersensitivity pneumonitis related to imatinib mesylate.
    Bergeron A; Bergot E; Vilela G; Ades L; Devergie A; Espérou H; Socié G; Calvo F; Gluckman E; Ribaud P; Rousselot P; Tazi A
    J Clin Oncol; 2002 Oct; 20(20):4271-2. PubMed ID: 12377975
    [No Abstract]   [Full Text] [Related]  

  • 23. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment.
    Ikeda K; Shiga Y; Takahashi A; Kai T; Kimura H; Takeyama K; Noji H; Ogawa K; Nakamura A; Ohira H; Sato Y; Maruyama Y
    Leuk Lymphoma; 2006 Jan; 47(1):155-7. PubMed ID: 16321842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia.
    Govind Babu K; Attili VS; Bapsy PP; Anupama G
    Int Ophthalmol; 2007 Feb; 27(1):43-4. PubMed ID: 17410337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia.
    Pou M; Saval N; Vera M; Saurina A; Solé M; Cervantes F; Botey A
    Leuk Lymphoma; 2003 Jul; 44(7):1239-41. PubMed ID: 12916879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disseminated erythematous and pityriasiform plaques caused by imatinib mesylate.
    Pasmatzi E; Monastirli A; Matsouka P; Tsambaos D
    Acta Derm Venereol; 2003; 83(5):391-2. PubMed ID: 14609118
    [No Abstract]   [Full Text] [Related]  

  • 27. Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia.
    Jørgensen HG; Copland M; Holyoake TL
    Cancer; 2005 Jan; 103(1):210-11. PubMed ID: 15540243
    [No Abstract]   [Full Text] [Related]  

  • 28. Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back.
    Alwan AF; Matti BF; Naji AS; Muhammed AH; Abdulsahib MA
    Leuk Lymphoma; 2014 Dec; 55(12):2830-4. PubMed ID: 24628295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.
    Cervantes F; López-Garrido P; Montero MI; Jonte F; Martínez J; Hernández-Boluda JC; Calbacho M; Sureda A; Pérez-Rus G; Nieto JB; Pérez-López C; Román-Gómez J; González M; Pereira A; Colomer D
    Haematologica; 2010 Aug; 95(8):1317-24. PubMed ID: 20220063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unusual fluid retention with imatinib therapy for chronic myeloid leukemia.
    Ostro D; Lipton J
    Leuk Lymphoma; 2007 Jan; 48(1):195-6. PubMed ID: 17325868
    [No Abstract]   [Full Text] [Related]  

  • 31. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
    Kong JH; Yoo SH; Lee KE; Nam SH; Kwon JM; Lee SM; Chang HJ; Choi MY; Cho MS; Mun YC; Nam E; Lee SN; Seong CM
    Acta Haematol; 2007; 118(4):205-8. PubMed ID: 18030002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Imatinib combination therapies--the new CML Study 4].
    Helmann R; Berger U; Engelich G
    Dtsch Med Wochenschr; 2002 Oct; 127(42):224-6. PubMed ID: 12430568
    [No Abstract]   [Full Text] [Related]  

  • 33. Imatinib mesylate-induced acute hepatitis with autoimmune features.
    Dhalluin-Venier V; Besson C; Dimet S; Thirot-Bibault A; Tchernia G; Buffet C
    Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1235-7. PubMed ID: 17033447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insufficient bilateral femoral subtrochanteric fractures in a patient receiving imatinib mesylate.
    Yang KH; Park SY; Park SW; Lee SH; Han SB; Jung WK; Kim SJ
    J Bone Miner Metab; 2010 Nov; 28(6):713-8. PubMed ID: 20607326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imatinib-associated pulmonary alveolar proteinosis.
    Wagner U; Staats P; Moll R; Feek U; Vogelmeier C; Groneberg DA
    Am J Med; 2003 Dec; 115(8):674. PubMed ID: 14656624
    [No Abstract]   [Full Text] [Related]  

  • 36. Imatinib-induced immune hepatitis: case report and literature review.
    Al Sobhi E; Zahrani Z; Zevallos E; Zuraiki A
    Hematology; 2007 Feb; 12(1):49-53. PubMed ID: 17364993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imatinib-induced erythroderma.
    Mathew T; Chandrashekar L; Pulimood S; Srivastava A
    Australas J Dermatol; 2007 Aug; 48(3):193-4. PubMed ID: 17680975
    [No Abstract]   [Full Text] [Related]  

  • 38. Imatinib mesylate induced immune thrombocytopenia.
    Rajappa S; Varadpande L; Paul TR; Digumarti R
    Leuk Lymphoma; 2007 Nov; 48(11):2261-3. PubMed ID: 17926182
    [No Abstract]   [Full Text] [Related]  

  • 39. Histological features of acute hepatitis after imatinib mesylate treatment.
    James C; Trouette H; Marit G; Cony-Makhoul P; Mahon FX
    Leukemia; 2003 May; 17(5):978-9. PubMed ID: 12750713
    [No Abstract]   [Full Text] [Related]  

  • 40. Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy.
    Rajda J; Phatak PD
    Am J Hematol; 2005 May; 79(1):80-1. PubMed ID: 15849772
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.